Publications

Gebbink MF, Bouma B, Maas C, Bouma BN. (2009). Physiological responses to protein aggregates: fibrinolysis, coagulation and inflammation (new roles for old factors). FEBS Lett., 583, 2691-2699.

Maas, C, Govers-Riemslag, JWP, Bouma, B, Schiks, B, Hazenberg, B, Lokhorst, HM, Hammarström, P, ten Cate, H, de Groot, PG, Bouma, BN, Gebbink, MFBG. (2008). Factor XII is activated by misfolded proteins, which leads to kallikrein formation without initiating coagulation. J. Clin. Invest, 118, 3208-3218.

See also: Cell Biology Select, Cell 134(6), 893,895.

See also: The Science Business eXchange, read more.

Maas, C, Schiks, B, Strangi, R, Hackeng, TM, Bouma, BN, Gebbink, MFBG, Bouma, B (2008). Identification of fibronectin type I domains as amyloid-binding modules on tissue-type plasminogen activator and three homologues. Amyloid 15(3), 166-180.

Herczenik, E, Gebbink, MFBG (2008). Molecular and cellular aspects of protein misfolding and disease. FASEB J. 22, 2115-2133.

Herczenik, E, Bouma, B, Korporaal, SJ, Strangi, R, Zeng, Q, Gros, P, Van Eck, M, Van Berkel, TJ, Gebbink, MFBG, Akkerman, JW (2007). Activation of human platelets by misfolded proteins. Arterioscler Thromb Vasc Biol. 27(7), 1657-1665.

Bouma, B, Maas, C, Hazenberg, BP, Lokhorst, HM, Gebbink, MFBG (2007). Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses. J Thromb Haemost. 5(6):1139-1142.

Maas, C, Hermeling, S, Bouma, B, Jiskoot, W, Gebbink, MFBG. (2007). A role for protein misfolding in immunogenicity of biopharmaceuticals. J Biol Chem. 282(4): 2229-2236.

Hermeling, S, Schellekens, H, Maas, C, Gebbink, MFBG, Crommelin, DJA, Jiskoot, W (2006). Antibody response to aggregated human interferon alpha2b in wildtype and transgenic immune tolerant mice depends on type and level of aggregation. J. Pharm. Sci., 95(5), 1084-1096.

Gebbink, MFBG, Claessen, D, Bouma, B, Dijkhuizen, L, and Wösten, HAB (2005). Amyloid: a functional coat for microbes. Nat. Rev. Microbiol., 3, 333-339.

Kranenburg, O, Bouma, B. van Gent, YYJ, Aarsman, JA, Kayed, R, Posthuma, G., Schiks, B, Voest, EE and Gebbink, MFBG. (2005). b-Amyloid (Ab) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation. Mol. Cell. Neurosci. 28, 496-508.

Kranenburg, O, van Gent, YYJ, Romijn, EP, Voest, EE, Heck, AJR and Gebbink, MFBG (2005). Amyloid-b-stimulated plasminogen activation by tPA results in processing of neuroendocrine factors. Neuroscience 131, 877-886.

te Velde, E.A., Reijerkerk, A, Brandsma, D, Vogten, JM, Wu, Y, Kranenburg, O, Voest, EE, Gebbink, MFBG and Borel Rinkes, IHM. (2005). Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells. Br. J. Cancer. 92, 729-735.

Gebbink, MF, Voest, EE and Reijerkerk, A. (2004). Do anti-angiogenic protein fragments have amyloid properties? Blood 104, 1601-1605.

Vogten, JM, Reijerkerk, A, Meijers, JC, Voest EE, Borel-Rinkes, IH and Gebbink, MF (2003). The role of the fibrinolytic system in corneal angiogenesis. Angiogenesis 6, 311-316.

Bouma, B, Kroon-Batenburg, LM, Wu, YP, Brunjes, B, Posthuma, G, Kranenburg, O, de Groot, PG, Voest, EE, and Gebbink, MF (2003). Glycation induces formation of amyloid cross-beta structure in albumin. J. Biol. Chem. 278, 41810-41819.

See also: Perspective in Science's SAGE KE, 2004, pe3.

Reijerkerk A, Mosnier LO, Kranenburg O, Bouma, BN, Carmeliet, P, Drixler, T., Meijers, JC, Voest, EE, Gebbink, MF (2003). Amyloid endostatin induces endothelial cell detachment by stimulation of the plasminogen activation system. Mol Cancer Res. 1, 561-568.

Drixler, TA, Vogten, JM, Gebbink, MF, Carmeliet, P, Voest, EE, Borel Rinkes, IH (2003). Plasminogen mediates liver regeneration and angiogenesis after experimental partial hepatectomy. Br J Surg. 90, 1384-90.

Kranenburg, O., Kroon-Batenburg, LMJ, Reijerkerk, A, Wu, Y-P, Voest EE and Gebbink, MF (2003). Recombinant endostatin forms amyloid fibrils that bind and are cytotoxic to murine neuroblastoma cells in vitro. FEBS Lett. 539, 149-155.

Kranenburg, O., Bouma, B., Kroon-Batenburg, LM, Reijerkerk, A., Wu,YP, Voest, EE, and Gebbink, MF (2002). Tissue-type plasminogen activator is a multiligand cross-beta structure receptor. Curr. Biol. 12, 1833-1839.